While studying salmon populations and designing amusement parks, these students are breaking barriers to advanced math that ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10. Check out the current price of PRAX stock here. PRAX closed Thursday's regular ...

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Obviously, these are not topics that are outside the syllabus or the test blueprint,” he explained. WAEC’s provisional results for the 2025 WASSCE show that more than half of the candidates — 220,008 ...

The Head of Public Relations at the West African Examinations Council (WAEC), John Kapi, has attributed the sharp decline in core mathematics performance in the 2025 West African Senior School ...

The West African Examinations Council (WAEC) has confirmed a national education concern with the release of the provisional WASSCE 2025 results, revealing a worrying surge in the outright failure rate ...

Culper Research report argues that the data underpinning its essential tremor program cannot withstand regulatory scrutiny. According to the short report, Praxis engineered its October 2025 results ...

A new report from the University of California, San Diego has ignited a viral conversation on social media, because it demonstrates the alarming lack of preparation among incoming freshmen for college ...

A sharp rise in students entering the University of California system without middle school-level math skills is raising alarms among educators. A new internal report from the University of California ...

Praxis Precision Medicines surged after positive Essential3 data for ulixacaltamide in essential tremor, but tolerability issues limit enthusiasm. Ulixacaltamide demonstrated functional benefit, but ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...